Clinuvel Pharmaceuticals Limited
CUV.AX · ASX
Market closed9.92-0.190000 (-1.88%)
Key statistics
Previous close10.11
Open9.92
Day high10.15
Day low9.92
52-week high14.00
52-week low8.35
Market cap500.08M
Volume69.59K
Average volume99.85K
P/E ratio15.40
Forward P/E—
EPS0.64
Dividend yield+0.50%
Market context
Why it moved
In the absence of specific company-related news, CUV.AX (Clinuvel Pharmaceuticals) declined modestly today likely due to broader market selling pressure and profit-taking, with the stock retreating from its previous close amid subdued trading volumes.
What is happening
Recent company-specific developments and publisher coverage.
GlobeNewswire · July 13, 2026SCENESSE® approved for EPP in CanadaSimply Wall Street · April 25, 2026How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial DesignGlobeNewswire · April 24, 2026CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo studySimply Wall Street · February 27, 2026Clinuvel Pharmaceuticals H1 2026 Margin Compression Challenges Bullish Growth Narratives Mt Newswire · July 13, 2026Clinuvel Pharmaceuticals' Photoprotection Drug Candidate Receives Health Canada Approval Mt Newswire · July 2, 2026Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment Mt Newswire · June 16, 2026Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade Mt Newswire · April 28, 2026Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway Mt Newswire · April 27, 2026Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant Mt Newswire · April 27, 2026Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies Mt Newswire · April 24, 2026Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency Mt Newswire · April 13, 2026Clinuvel Pharmaceuticals Says JPMorgan Increases Stake